**Appendix E Histopathology worksheet for metastatic carcinoma of uncertain primary site**

Surname........................... Forenames......................... Date of birth................. Sex....... Hospital............................. Hospital no..........................
NHS/CHI no.................
Date of receipt.................... Date of reporting................... Report no.....................

**Carcinoma subtype: immunohistochemistry**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Panel** | **Specific immunohistochemical markers used** | **Positive**  | **Negative** | **Equivocal** |
| Adenocarcinoma |  |  |  |  |
| Squamous carcinoma |  |  |  |  |
| Transitional carcinoma |  |  |  |  |
| Neuroendocrine carcinoma |  |  |  |  |
| Solid carcinoma: renal |  |  |  |  |
| Solid carcinoma: liver |  |  |  |  |
| Solid carcinoma: thyroid |  |  |  |  |
| Solid carcinoma: adrenal |  |  |  |  |
| Germ cell tumour |  |  |  |  |
| Mesothelioma |  |  |  |  |

Result for CK7………………………… Result for CK20………………………………………..

Any other relevant IHC markers employed:…………………………………………………………………

……………………………………………………………………………………………………………………..

**Diagnosis (specific carcinoma subtype):**…………………………………………………………………..

**Adenocarcinoma subtyping: morphology**

|  |  |
| --- | --- |
| **Morphological pattern**  | **Present? (tick more than one if necessary)** |
| Poorly differentiated carcinoma |  |
| Adenocarcinoma NOS |  |
| Papillary adenocarcinoma |  |
| Signet ring cell/diffuse adenocarcinoma |  |
| Other specific morphology (describe) |  |

**Adenocarcinoma subtyping: immunohistochemistry**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Panel** | **Specific immunohistochemical markers used** | **Positive**  | **Negative** | **Equivocal** |
| Prostate |  |  |  |  |
| Lung |  |  |  |  |
| Breast |  |  |  |  |
| Ovary and other gynaecological |  |  |  |  |
| Colorectum |  |  |  |  |
| Gastro-oesophageal |  |  |  |  |
| Pancreatico-biliary |  |  |  |  |
| Other (specify) |  |  |  |  |

**Adenocarcinoma subtype diagnosis: …………………………………………………..**

**Any further comments especially for assessment of poorly differentiated malignancy:** ………………………………………………………………………………………………………